Lesley M. Shaw

  • Citations Per Year
Learn More
1 d Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease.” Biochemical biomarkers of late-life dementia Christopher M. Clark*, Domenico Pratico, Lesley M. Shaw, Susan Leight, Sharon X Xie, Amy Gu, Virginia M.-Y. Lee, and John Q. Trojanowski Department of Neurology, University of Pennsylvania,(More)
Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as well as target engagement when evaluating novel drug and therapeutic strategies. This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's(More)
  • 1